CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $2.96B, above the global median of $1.15B
- FinancialsAltman Z-Score 2.15: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
283.12BINR2.96B · vs all stocks (USD)
Revenue (TTM)
92.05BINR961.86M · vs all stocks (USD)
Profit Margin
-3.41%Beta
0.3240xvs all stocks
52-Week Change
10.81%vs all stocks
Market Capitalization
283.12BINR2.96B · vs all stocks (USD)
Enterprise Value
331.11BINR3.46B · vs all stocks (USD)
Forward P/E
53.19xPrice to Sales (TTM)
3.12xPrice to Book (MRQ)
3.52xEnterprise to Revenue
3.60xEnterprise to EBITDA
36.88xGross Margin
62.45%Profit Margin
-3.41%Operating Margin
-1.25%Return on Assets (TTM)
-1.81%Return on Equity (TTM)
-3.99%Revenue (TTM)
92.05BINR961.86M · vs all stocks (USD)
Revenue per Share (TTM)
69.24INRUpdated Aug 22, 2026Quarterly Revenue Growth
17.40%Gross Profit (TTM)
54.69BINR571.49M · vs all stocks (USD)
EBITDA (TTM)
12.58BINR131.46M · vs all stocks (USD)
Net Income (TTM)
-3.14BINR-32.77M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-14.79%Operating Cash Flow (TTM)
16.53BINR172.68M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-3.26BINR-34.06M · vs all stocks (USD)
Payout Ratio
15.07%Revenue
87.59BINRFY2026 · Mar 31, 2026Cost of Goods Sold
35.84BINRFY2026 · Mar 31, 2026Gross Profit
51.75BINRFY2026 · Mar 31, 2026Operating Income
1.55BINR16.19M · vs all stocks (USD)
Pre-tax Income
-1.76BINRFY2026 · Mar 31, 2026Income Tax Expense
1.50BINRFY2026 · Mar 31, 2026Net Income
-3.26BINRFY2026 · Mar 31, 2026EBIT
1.62BINRFY2026 · Mar 31, 2026EBITDA (Income Statement)
12.31BINRFY2026 · Mar 31, 2026Research & Development
1.11BINRFY2026 · Mar 31, 2026Selling, General & Administrative
6.52BINRFY2026 · Mar 31, 2026Other Operating Expenses
10.85BINRFY2026 · Mar 31, 2026Non-operating Interest Income
70.70MINRFY2026 · Mar 31, 2026Non-operating Interest Expense
3.38BINRFY2026 · Mar 31, 2026EPS (Basic)
-2.46INRFY2026 · Mar 31, 2026EPS (Diluted)
-2.46INRFY2026 · Mar 31, 2026Basic Shares Outstanding
1.33BSharesFY2026 · Mar 31, 2026Diluted Shares Outstanding
1.33BSharesFY2026 · Mar 31, 2026Net Income from Continuing Operations
-2.33BINRFY2026 · Mar 31, 2026Minority Interests (P&L)
0.00INRFY2026 · Mar 31, 2026Preferred Stock Dividends
0.00INRFY2026 · Mar 31, 2026Operating Cash Flow
305.10MINRFY2026 · Mar 31, 2026Free Cash Flow
-8.46BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents (End of Period)
9.76BINRFY2026 · Mar 31, 2026Starting Profit (CF Statement)
-2.33BINRFY2026 · Mar 31, 2026Stock-based Compensation
417.20MINRFY2026 · Mar 31, 2026Other Non-cash Items
5.06BINRFY2026 · Mar 31, 2026Change in Accounts Receivable (CF)
2.17BINRFY2026 · Mar 31, 2026Change in Other Assets/Liabilities
-5.01BINRFY2026 · Mar 31, 2026Capital Expenditures
-8.77BINRFY2026 · Mar 31, 2026Purchase of Investments
-9.92BINRFY2026 · Mar 31, 2026Sale of Investments
9.97BINRFY2026 · Mar 31, 2026Net Investing Cash Flow
-8.72BINRFY2026 · Mar 31, 2026Long-term Debt Issuance
9.03BINRFY2026 · Mar 31, 2026Long-term Debt Payments
-15.67BINRFY2026 · Mar 31, 2026Net Short-term Debt Issuance
9.85BINRFY2026 · Mar 31, 2026Common Dividends Paid
-185.50MINRFY2026 · Mar 31, 2026Net Financing Cash Flow
3.05BINRFY2026 · Mar 31, 2026Shares Outstanding
1.33BSharesUpdated Aug 22, 2026Float Shares
610.63MSharesUpdated Aug 22, 2026% Held by Insiders
54.53%vs all stocks
% Held by Institutions
21.13%vs all stocks
Total Cash (MRQ)
13.55BINR141.63M · vs all stocks (USD)
Total Cash per Share (MRQ)
10.21INRUpdated Aug 22, 2026Total Debt (MRQ)
57.12BINR596.84M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.6998xCurrent Ratio (MRQ)
1.51xBook Value per Share (MRQ)
61.50INRUpdated Aug 22, 2026Total Assets
179.65BINR1.88B · vs all stocks (USD)
Total Current Assets
71.92BINRFY2026 · Mar 31, 2026Total Liabilities
98.02BINRFY2026 · Mar 31, 2026Total Non-current Assets
107.73BINRFY2026 · Mar 31, 2026Total Non-current Liabilities
50.44BINRFY2026 · Mar 31, 2026Total Current Liabilities
47.58BINRFY2026 · Mar 31, 2026Cash
9.75BINRFY2026 · Mar 31, 2026Cash Equivalents
2.25BINRFY2026 · Mar 31, 2026Cash & Cash Equivalents
12.00BINRFY2026 · Mar 31, 2026Other Short-term Investments
1.35BINRFY2026 · Mar 31, 2026Accounts Receivable
21.58BINRFY2026 · Mar 31, 2026Inventory
30.64BINRFY2026 · Mar 31, 2026Accounts Payable
24.79BINRFY2026 · Mar 31, 2026Short-term Debt
12.39BINRFY2026 · Mar 31, 2026Other Current Liabilities
843.10MINRFY2026 · Mar 31, 2026Long-term Debt
44.35BINRFY2026 · Mar 31, 2026Other Non-current Liabilities
1.56BINRFY2026 · Mar 31, 2026Common Stock (Book)
13.27BINRFY2026 · Mar 31, 2026Retained Earnings
6.92BINRFY2026 · Mar 31, 2026Total Shareholders' Equity
81.63BINR852.91M · vs all stocks (USD)
52-Week Low
132.30INRUpdated Aug 22, 202652-Week High
220.36INRUpdated Aug 22, 202652-Week Change
10.81%vs all stocks
Beta
0.3240xvs all stocks
50-Day MA
182.96INRUpdated Aug 22, 2026200-Day MA
168.73INRUpdated Aug 22, 2026Avg 10-Day Volume
4.90MSharesUpdated Aug 22, 2026Avg 30-Day Volume
6.80MSharesUpdated Aug 22, 2026Diluted EPS (TTM)
-2.37INRUpdated Aug 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.62Profit Margin: -0.03
Financial Health
Altman Z-Score 2.15: grey zoneSignificant
Altman Z-Score: 2.15
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $2.96B, above the global median of $1.15BNotable
Market cap (USD): 2,958,286,312.451Global Median: 1,146,734,693.424
Revenue is $961.86M, above the global median of $520.53MNotable
Revenue (USD): 961,860,729.029Global Median: 520,528,949.311
Companies that share the same coordination system — how they create, deliver, or capture value.
Yili Chuanning Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Autobio Diagnostics Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Rubicon Research Limited
Tier 1ProductionApproval-Gated PipelineRule
Walvax Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
MBX Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Disc Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ultragenyx Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Pharma Research Products Co., Ltd
Tier 1ProductionApproval-Gated PipelineRule
Kangmei Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Chengdu Kanghong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule